Inherited monogenic palmoplantar keratodermas are a heterogeneous group of conditions characterized by persistent epidermal thickening of the palmoplantar skin. Palmoplantar keratodermas are grouped depending on the morphology of the keratoderma into diffuse, focal/striate or papular/punctate. Some palmoplantar keratodermas just affect the skin of the palms and soles and others have associated syndromic features which include changes in hair, teeth, nails, hearing loss or cardiomyopathy. Next generation sequencing has helped discover genes involved in many of these conditions and has led to reclassification of some palmoplantar keratodermas. In this review, we discuss the diagnostic features of palmoplantar keratodermas and management options.

Key words: keratoderma; palmoplantar; keratin; genetic; inherited.

Accepted Feb 12, 2020; Epub ahead of print Mar 9, 2020

Acta Derm Venereol 2020; 100: adv00094.

Corr: Prof. Edel A. O’Toole, Centre for Cell Biology and Cutaneous Research, The Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, and Department of Dermatology, Royal London Hospital, Barts Health NHS Trust, E-mail: e.a.otool@qmul.ac.uk

An initial approach to PPK is to take a history asking about age of onset, palmoplantar pain and/or blistering, sweating and infection and other associated features including hearing loss, abnormal hair, nail or teeth/mucosal problems, cysts and family history including family history of cancer. Clinical examination can usually differentiate PPK into 3 groups: diffuse, focal or punctate (Fig. 1). The clinical features and management will be discussed in this review and are summarized in Table I.

Diffuse epidermolytic PPK (EPPK; MIM# 144200, KRT9, KRT1) is the most common diffuse PPK with epidermolytic changes in suprabasal keratinocytes seen on histology (4). It is inherited in an autosomal dominant (AD) fashion due to mutations in KRT9 and sometimes KRT1 (5, 6). The KRT9 gene encodes for the type I keratin, keratin 9, which is mainly expressed in suprabasal palmoplantar skin. Type I keratins form heterodimers with type II keratins, in this instance, possibly keratin 1, found in the epidermis inclu...
### Table I. Summary of hereditary palmoplantar keratodermas (HPPK)

| Type                                  | MIM(#)   | Gene             | Inheritance | Features                                                                 | Trangrediens | Superinfection | Specific Treatment                                                                 |
|---------------------------------------|----------|------------------|-------------|---------------------------------------------------------------------------|--------------|----------------|------------------------------------------------------------------------------------|
| DIFFUSE HPPK: NO ASSOCIATED FEATURES  |          |                  |             |                                                                           |              |                |                                                                                     |
| EPPK                                  | 144200   | KRT9 (KRT1)      | AD          | Brown-yellow, fissuring                                                  | Limited in KRT1 | Very occasional | Keratolytics, Retinoids, Calcipotriol                                                |
| NEPPK type Bothnia                    | 600231   | AQP5             | AD          | Brown-yellow, smooth, White-spongy with water immersion                  | No           | Bacterial      | Fungal, treat superinfection                                                        |
| NEPPK type Nagashima                  | 615598   | SERPINB7         | AR          | Mild hyperkeratosis, Erythema +++, extension to dorsal acral surfaces, spongy with water immersion | No           | Bacterial      | Treat superinfection, treat hyperhidrosis                                           |
| MDM                                   | 284300   | AR               | AR          | Thick ivory macerated hyperkeratosis, malodour, lesions on elbows and knees, contractibands | Yes          | Bacterial      | Fungal, treat superinfection, treat hyperhidrosis, Retinoids – hyperkeratosis improves; erythema worsens |
| DIFFUSE HPPK: NO ASSOCIATED FEATURES  |          |                  |             |                                                                           |              |                |                                                                                     |
| LK                                    | 604117   | LOR              | AD          | Collodion +/-, generalised scaling, diffuse honeycomb PPK, extensor surface fixed plaques, contractibands | Yes – ill-defined | No             | Isotretinoin                                                                       |
| KLICK                                 | 601952   | POMP             | AR          | Ichthyosis similar to LK, smooth PPK, flexural linear & starfish keratosis on large joints | No           | No             | Acitretin                                                                          |
| PPK with scleroatroph (Huriez)        | 181600   | SMARCAD1         | AR          | Scleroatroph on palms/fingers, mild hyperkeratosis, erythema, palms > soles, 100x risk SCC | No           | No             | Acitretin – PPK/SCC                                                                 |
| Palmoplantar hyperkeratosis with SCC & sex reversal | 610644   | RSP01            | AR          | Similar to Huriez syndrome                                                | No           | No             | Acitretin                                                                          |
| OODD                                  | –        | WNT10A           | AR          | Mild PPK, diffuse, erythematous, late onset hyperhidrosis, overlap with SPSS – ectodermal abnormalities, late onset hidrocystomas | No           | No             | Surgery/laser – tumours & cysts                                                     |
| OLS                                   | 614594   | TRPV2 MTB5R2     | AD, AR, Semi-dominant, XLR | Diffuse PPK, digital flexion deformities, contractibands, perifonial keratoses | No           | Bacterial      | Variable response to acitretin, Surgery +/- grafting for PPK, *EGFR inhibitors |
| OLS                                   | 300918   |                  |             |                                                                           |              |                |                                                                                     |
| PLS                                   | 245000   | CTSC             | AR          | Thickening/erythema palmoplantar skin, peronitis, No hyperkeratotic plaques on extensors, HMS also has skeletal changes | No           | No             | Fungal, Dental care essential Tetracyclines (>12y/o)                               |
| HMS                                   | 245010   |                  |             |                                                                           |              |                |                                                                                     |
| CEDNIK                                | 609528   | SNAP29           | AR          | Diffuse keratoderma & ichthyosis, neurological manifestations              | No           | No             | Symptomatic                                                                        |
| ARKID                                 | –        | VPS33B           | AR          | Progressive hearing loss, diffuse PPK, flexion deformities, contractibands | No           | No             |                                                                                     |
| PPK, leukonychia, exuberant scalp hair | –        | FAM83G           | AR          | Diffuse, verrucous thickening, soles > palms                               | No           | No             |                                                                                     |
| FOCAL PPK: NO ASSOCIATED FEATURES     |          |                  |             |                                                                           |              |                |                                                                                     |
| PPKS1                                 | 148700   | DSG1             | AD          | Linear bands of hyperkeratosis on palm. Plantar surface typically focal and precede palms. | No           | No             | Keratolytics                                                                       |
| PPKS2                                 | 612908   | DSP1             | –           |                                                                           | No           | No             |                                                                                     |
| PPKS3                                 | 607654   | KRT1             | –           |                                                                           | No           | No             |                                                                                     |
| FOCAL PPK: ASSOCIATED FEATURES        |          |                  |             |                                                                           |              |                |                                                                                     |
| TOC                                   | 148500   | RHBD2            | AD          | PPK by 8 years of age, follicular hyperkeratosis/oral leukokeratosis (cf PC), Oesophageal carcinoma – 95% risk by 65 years of age | No           | No             | Screening of carcinoma Avoid smoking and alcohol                                   |
| Tyrosinaemia type II                  | 276600   | TAT              | AR          |                                                                           | No           | No             | Phenylalanine/tyrosine free diet                                                     |
| PC                                    | Multiple MIM# | KRTR6A,6B, 6C, 16,17 | AD | Ocular symptoms – photophobia and scarring, hyperkeratosis of dermatoglyphs → focal PPK | No           | No             | Mechanical debridement Acitretin – low dose Botox Rapamycin                          |
| PPK-deafness syndromes                | Multiple MIM# | GB2 (GB6) | AD | PPK with hearing loss. Volkwinkel syndrome – marginal translucent papules, contractibands | No           | No             | Acitretin/surgery – contractibands                                                   |
| PPK & Cardiomyopathy                  | 601214 (Naxos) | JUP        | AR           | Woolly hair at birth with diffuse/striped PPK. Naxos – cardiomyopathy in adolescence. Carvajal – cardiomyopathy earlier in life | No           | No             | Woolly hair and PPK → cardiac investigations for patient and family |
The palms and soles, to form intermediate filaments which provide strength to the skin (7, 8).

This PPK develops in infancy and in adults the hyperkeratosis is brown-yellow and confluent with fissuring, confined to the palmoplantar surfaces with an erythematos edge. Limited transgradient lesions or flexural hyperkeratosis may indicate KRT1 mutations (9). There may be a history of blistering and knuckle pads have been reported.

Treatment is mainly by mechanical debridement and use of keratolytics like urea, salicylic acid and lactic acid in emollient, sometimes under occlusion. Oral retinoids can help but pain from increased fragility limits their use (10, 11). Topical calcipotriol has been reported to be of benefit (12). Small inhibitory RNA therapy may be a possibility for the future (13).

DIFFUSE NON-EPIDERMOLYTIC PALMO PLANTAR KERATODERMAS

Non-epidermolytic PPK type Bothnia (MIM# 600231, AQP5) was first described in Northern Sweden and is due to heterozygous missense mutations in AQP5 (14). This gene encodes for the water-channel protein aquaporin-5, which is expressed in exocrine glands but also the plasma membrane of palmar stratum granulosum. Mutations in the gene allow these cells to transport water by forming open water channels at this site.

This PPK usually starts in the first few months of life and is classically a brown-yellow, smooth keratoderma with an erythematos edge. Due to the defect in aquaporins, water immersion leads to a white spongy appearance which lasts for about 30 min. Pitted keratolysis and dermatophyte superinfection is common and can be treated with topical erythromycin or oral anti-fungals (15). Acitretin at low doses can be helpful.

NEPPK type Nagashima (MIM# 615598, SERPINB7) is an autosomal recessive (AR) PPK due to mutations in SERPINB7 described in Japanese and Chinese patients. Mutations in this gene may cause uncontrolled activity of proteases in the stratum corneum leading to increased water permeation (16, 17).

The condition presents in early life and is characterised by mild hyperkeratosis and striking redness extending to the dorsum fingers/feet and anterior wrist (18). A white spongy appearance after water immersion is seen (19) and associated hyperhidrosis and bacterial/fungal superinfection can be present.

Mal de Meleda (MDM; MIM#248300, ARS) is an eponymous AR PPK named after the Island of Mljet (née Meleda) (20). Mutations in ARS which encodes SLURP-1 cause MDM (21). SLURP-1 stimulates nicotinic acetylcholine receptors which regulate keratinocyte growth. When SLURP-1 is not functioning, it is thought that there is a reduction in keratinocyte apoptosis regulation (22).

MDM is characterised by a diffuse, ivory-yellow maturated hyperkeratosis with a characteristic malodour and...
striking erythematous transgadiens that extends to dorsal surfaces. A key feature includes lesions on the elbows and knees (21). Perioral hyperkeratosis and erythema can be present (23). The disease starts in infancy and progresses through life. Flexion contractures can occur and constrictive bands can lead to spontaneous amputation (24). Nail thickening, subungual hyperkeratosis and koilonychia can be present. The diffuse keratoderma of Gamborg-Nielsen also due to ARS mutations is likely a mild variant of MDM (25). Interestingly female heterozygotes can also present with a mild phenotype (26).

Treatment of bacterial/fungal superinfection and the hyperhidrosis is helpful, although the mainstay of treatment is oral retinoids which improve the hyperkeratosis although the erythema may worsen (27, 28).

**DIFFUSE HEREDITARY PALMOPPLANTAR KERATODERMAS: WITH ASSOCIATED FEATURES**

Loricrin keratoderma (LK; MIM# 604117, LOR) is AD and starts in early childhood. It is due to a mutation in LOR which interferes with the regulation of epidermal cornification (29). Some children are born with a colloidion membrane and generalised scaling from birth may be noted (30). During childhood the PPK develops with a characteristic diffuse, honeycomb pattern which can extend to wrist/ankles and is associated with non-migratory red plaques on the extensor surfaces of joints (31). Transgadiens is present but the edges of the hyperkeratosis are ill-defined. Constrictive bands can develop. Knuckle pads may be present (32) and hearing is intact.

Isotretinoin has been reported as helpful (33). In the future, there may be a role for treating LK with vascular endothelial growth factor 2 receptor inhibitors (34).

Keratosis linearis with ichthyosis congenita and scle-roizing keratoderma (KLICK, MIM#601952, POMP) presents in early childhood and similar to LK, starts with generalised erythema and fine scaling with the subsequent diffuse, smooth PPK (35). Inheritance of this PPK is AR caused by mutations in the POMP gene, which lead to endoplasmic reticular stress and subsequent dysfunctional profilaggrin processing (36, 37). Flexural linear and starfish keratoses overlying large joints are distinctive (35). Acitretin can be helpful for both the ichthyosis and keratoderma (38).

PPK with scleroatrophy (Huriez syndrome, MIM #181600) is a cancer-related PPK caused by haploinsufficiency in SMARCA2 (39). Scleroatrophy is seen across the entire palm and fingers (40) with mild hyperkeratosis of the palms. The affected skin is often red and the palms are usually more severely affected than the soles. Hypoplastic nail changes may be present and 50% experience hyperhidrosis. The most important characteristic is the 100-fold increased risk of developing squamous cell carcinoma (SCC) in the affected skin. Acitretin may be helpful for the PPK and prevention of SCC (41).

Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM#610644, RSPO1) is similar to Huriez syndrome as it is a mild PPK with sclerodactyly and nail hypoplasia (42). This condition is AR caused by mutations in RSPO1 (43). This gene is responsible for stabilising β-catenin in the Wnt signaling pathway which antagonises SRY/SOX9 actions for sex determination (44). A characteristic feature is the female to male sex reversal seen in females. The karyotype is 46, XX. Predisposition for cutaneous SCC and also laryngeal SCC is noted (45). Periodontitis with loss of teeth may be present.

Odonto-onycho-dermal dysplasia spectrum (OODD) is an AR condition caused by mutations in WNT10A which starts in early life (46). In absence of WNT10A, β-catenin pathway activity and epithelial progenitor proliferation are reduced. In these patients, Wnt-active stem cells are seen in sweat ducts, hair follicles, nails and taste buds and there are differentiation abnormalities in palmoplantar skin (47).

Typically the PPK is mild, diffuse and erythematous with late onset palmoplantar hyperhidrosis (48). There is overlap with Schöpf-Schulz-Passarge syndrome (SSPS) and patients can have hypodontia with abnormal teeth, nail hypoplasia, smooth tongue and hypotrichosis (49). Eyelid hidrocystomas and other benign adnexal tumours can present at a later age (50). Biopsy of palmoplantar skin shows eccrine syringoadenomatosis (46). Tumours/cysts may need treatment with surgery or laser.

Olmsted syndrome (OLS; MIM# 614594 – TRPV3, 300918 – MBTPS2) typically presents as a severe mutilating transgradient keratoderma. AD, AR, semi-dominant and X-linked recessive (XLR) forms have been described caused by mutations in TRPV3 (AD, AR) and MBTPS2 (XLR) (51, 52) The Ca2+-permeable cation channel TRPV3 is expressed abundantly in keratinocytes, associated with TGF-α/EGFR signalling and may play a role in keratinocyte differentiation by elevating Ca2+ within these cells (53). MBTPS2 mutations in skin may cause a decrease in responsiveness to sterols subsequent to depletion of proteases (54).

The keratoderma is diffuse and can be associated with digital flexion deformities and constrictive bands. Periorificial/ear/nose/umbilical keratoses can also be present. Dystrophy of teeth, nails and cornea, alopecia, erythromelalgia and joint laxity have also been reported. A milder phenotype can simulate pachyonychia congenita (PC) (55). Melanoma and SCC have been reported in OLS (56).

Treatment in general is difficult with variable response to systemic retinoids. Topical anti-inflammatories can be helpful for hyperkeratosis and itching. Surgery with excision and grafting of the keratoderma can lead to more favourable long-term outcomes (2). Finally, there has been one report of a patient treated with the EGFR inhibitor, erlotinib, which gave a transient improvement (57). PPK with periodontitis (MIM#245000, allelic disease: Haim-Munk #245010, CTSC) encapsulates both Papillon-Lefèvre syndrome (PLS) and Haim-Munk syndrome.
(HMS). Both conditions are caused by homozygous mutations in CTSC. CTSC is expressed in the palms, soles, alveolar bone and keratinized gingiva; it plays a role in immune cell protease activation and possibly has a role in epidermal differentiation leading to this particular phenotype (58, 59).

Patients have thickening and erythema of the palmoplantar skin, associated with bacterial skin infections and periodontitis (60). The PPK typically starts/worsens with the breakthrough of the deciduous teeth and actually improves after tooth loss/reduction of gingival inflammation (61). Hyperkeratotic plaques on the extensor surfaces are seen. PLS is associated with pyogenic liver abscesses (62). HMS has the same features with arachnodactyly, onychogryphosis and acro-osteolysis, mainly described in Cochin Jews (63).

Retinoids have shown to improve the PPK and oral disease (62). Specialist dental care is essential. For those above the age of 12, low dose tetracycline may be helpful for gingivitis, even at subtherapeutic doses (64).

Cerebral dysgenesis, neuropathy, ichthyosis and PPK syndrome (CEDNIK; MIM#609528, SNAP29) is a PPK with neurological manifestations which starts in infancy. This AR condition is caused by mutations in SNAP29 which lead to abnormal lamellar granule formation with subsequent aberrant epidermal differentiation (65). Around one year of age a diffuse keratoderma and ichthyosis become apparent (65, 66). Histology of CEDNIK demonstrates clear vesicles in the top 3 layers of the epidermis. Treatment is symptomatic.

Autosomal recessive keratoderma ichthyosis and deafness (ARKID) is caused by mutations in VPS33B. Mutations in this gene can lead to abnormal lamellar body morphology and function and impaired barrier formation. Patients present with progressive hearing loss (normal at birth) and delayed development. The PPK that develops is diffuse and associated with flexion deformities and autoamputation (67).

PPK, leukonychia and exuberant scalp hair is caused by AR mutations in FAM83G. FAM83G may have a role as a suppressor of the Wnt signalling pathway. Diffuse, verrucous thickening of soles and mild palmar involvement is noted. Leukonychia/dystrophy of the toenails and rapid hair growth are also seen (68).

Classically, striate PPK presents with linear bands of hyperkeratosis on the palmar surface (73). Diffuse or focal changes may also be present. It is usual for plantar changes to be focal and to present early in life (i.e. first or second year) and the palmar changes follow (71). If patients exhibit woolly/curl hair or abnormal dentition associated cardiomyopathy should be considered. Histology in PPKS can be helpful as it will demonstrate acantholysis of keratinocytes pointing to a desmosomal mutation (74).

FOCAL HEREDITARY PALMOPLANTAR KERATODERMAS: WITH ASSOCIATED FEATURES

Tylosis with oesophageal cancer (TOC; MIM#148500, RHBDF2) is rare condition that is AD and caused by gain of function mutations in RHBDF2 which create a hyperproliferative phenotype through continuous EGFR signalling (75). Patients present with focal keratoderma at sites of pressure usually by 8 years of age. Patients also have follicular hyperkeratosis and oral leukokeratosis similar to PC (76). Most patients with tylosis have a family history of oesophageal carcinoma and carry a risk of oesophageal cancer of 95% by age 65 years (77). Regular screening for oesophageal dysplasia is required and smoking and alcohol should be avoided.

Tyrosinaemia type II (MIM#276600, TAT) (78) is a very rare AR condition that initially presents in the first few months of life with ocular symptoms including photophobia and pain and subsequent ocular scarring (79). Hyperkeratosis of the palms that follows the fingerprints develops prior to a focal plantar keratoderma (80). About 50% of patients will have some form of intellectual disability and neurological signs. Increased tyrosine levels found in the bloods/urine, due to abnormal tyrosine aminotransferase function, can aid diagnosis (79) and symptoms may be prevented by a phenylalanine/tyrosine free diet.

Pachyonychia congenita (PC; Multiple MIM##) is a heterogeneous groups of conditions characterised by nail dystrophy and a painful focal keratoderma. The Pachyonychia Project (www.pachyonychia.org) has collected extensive data on PC collated in the International PC Research Registry (IPCRR). The current classification is based on keratin gene mutation: PC-6a, PC-6b, PC-6c, PC-16 and PC-17 (81). These 5 subtypes have replaced the original PC type 1 and 2 classification. Mutations in these genes lead to increased palmoplantar skin fragility due to disruption of keratin filament formation, nail changes and changes in the pilosebaceous unit.

The IPCRR data has shown that 90% of patients > 3 years old will have 3 clinical features: toenail dystrophy, plantar keratoderma and plantar pain (82). The hypertrophic nail dystrophy starts in the first few months of life up to 9 years. KRT6A mutations are associated with early onset disease. All nails need not be affected. The focal plantar keratoderma starts when children begin to weight bear with blistering under the calluses (83). Plantar pain...
has a neuropathic component and can be severe enough to require ambulatory aids. The palmar lesions are usually less prominent than the plantar lesions, except in the case of PC-KRT16 with striate lesions (82).

Follicular hyperkeratoses are seen in areas of friction. Oral leukokeratosis can resemble oral candidiasis and laryngeal involvement can lead to hoarseness and infantile respiratory obstruction (83). Cysts occur in all subtypes of PC although KRT17 mutations are usually associated with more steatocystomas/pilosebaceous cysts and natal teeth (less commonly KRT6A) (83). KRT6A mutations can also be associated with ear pain with feeding difficulties in infants/toddlers. PC-6C has a limited keratoderma and mild nail dystrophy (84).

Current treatment is largely mechanical paring of the calluses, assisted by a podiatrist, if necessary. Low dose acitretin can help in some patients but is associated with increased pain. Botox injections can also help reduce pain (85). The IPPC has had some promising results with siRNA and rapamycin (86, 87). Clinical trials of topical rapamycin are ongoing. As with most PPKs, comfortable foot wear and customised insoles are helpful.

Hypotrichosis-osteoelysis-periodontitis-palmoplantar keratoderma syndrome (HOPP; MIM 607658) is a rare syndrome with a phenotype similar to PLS/HMS although CTSC mutations were not found. There is a striking keratoderma with a reticular pitted/punctate pattern (88). Progressive hypotrichosis from 6 years of age is seen sometimes with pili annulati. Lingua plicata can be noted at an early age (89).

PPK-deafness syndromes are mainly caused by GJB2 and rarely GJB6 mutations. Numerous gap junctions are present in the skin and inner ear. Mutations in gap junction genes lead to abnormal keratinocyte differentiation/growth and dysfunctional inner ear potassium ion recycling required for hearing (90).

Phenotypically these PPK-deafness syndrome are distinct and still carry their eponymous names. Despite having mutations in the same gene, keratitis-ichthyosis-deafness-like (MIM# 148210), hystrix-like ichthyosis-deafness (MIM#602540), palmoplantar keratoderma-deafness (MIM#148350), Bart-Pumphrey (MIM# 149200) and Vohwinkel (MIM#124500) syndromes have phenotypic differences likely explained by mutations in particular domains of connexin 26 (GJB2) (91). Cardinal features are PPK and hearing loss of varying severity. For example, Vohwinkel syndrome has marginal translucent papules which become confluent over time. It also has the ‘classic’ starfish keratoses on the knuckles and extensor surfaces of joints and pseudoainhum (92).

Oral retinoids are helpful for the constricting bands seen in Vohwinkel syndrome (93) but surgery may be required.

PPK and cardiomyopathy are similar to PPKS1&2 as they are also associated with keratinocyte disadhesion. Naxos syndrome (AR) caused by mutations in JUP (MIM# 601214) encoding plakoglobin presents with woolly hair at birth followed by a diffuse/striate keratoderma in the first year of life. Cardiomyopathy presents in adolescence and has 100% penetrance (94). Carvajal-Heurtia syndrome (CHS), caused by mutations in DSP (MIM# 605676), is like Naxos although the cardiomyopathy presents earlier in the teens and is usually biventricular. Some patients with CHS have short woolly hair and keratoses on the elbows/knees (95, 96). The DSP and JUP genes encode desmosomal proteins required for formation of cell junctions in hair, skin and cardiac tissue (97). Mutations in KANK2 can cause woolly hair, hypotrichosis and a PPK without cardiac involvement (98). The KANK2 gene regulates steroid receptor coactivators. Patients with a striate keratoderma/PPK and woolly hair should have cardiac investigations. Family members should also be screened as these can have AR or AD inheritance.

**PAPULAR HEREDITARY PALMOPLANTAR KERATODERMAS: NO ASSOCIATED FEATURES**

Punctate PPK occurs in 1 in 100,000 people and has AD inheritance. Mutations in the AAGAB gene occur in about 1/3 (99). The AAGAB gene is involved in recycling of EGFR proteins and impairment in this function leads to keratinocyte proliferation (100). Also, mutations in COL14A1, encoding collagen XIV required for fibrillogenesis, have been found in Chinese families (101). Lesions seem to develop after the teenage years. Lesions are typically papular sometimes coalescing into plaques (102). The lesions are worse in manual labourers. Rarely, there is an association with malignancy (99). Treatment with mechanical debride ment is helpful. Comfortable shoes are key. Acitretin and altretinoin can be helpful for some (103).

Marginal papular keratoderma describes acrokerato-elastoidosis (AKE) and focal acral hyperkeratosis (FAH), thought to be inherited in an AD manner. AKE is characterized by small crateriform papules along ‘Wallace’s’ line on the medial aspect of the foot and the border of the palmar thenar/hyponthenar eminences (104). FAH, differentiated by the lack of fragmented dermal elastic fibres on histology, is associated with knuckle pads and hyperkeratosis extending onto the Achilles tendon (105) presenting in the teenage years in individuals of African or Afro-Caribbean ethnicity.

Transient Aquagenic keratoderma (TAK) is an unusual keratoderma that mainly effects the palms and is triggered by contact with water or sweat. Patients are typically young women and after a few minutes of exposure to water a fine white papular eruption is present on the palms (106). The eruption resolves after drying, leaving minimal hyperkeratosis. TAK can be differentiated from hereditary papulotranslucent acrokeratoderma (MIM 101840) as the papules in TAK do not persist. Aquagenic wrinkling of the palms, seen in 50% of patients with cystic fibrosis and 10% of CFTR mutation heterozygotes, can also look similar (107).
PAPULAR HEREDITARY PALMOPLANTAR KERA-TODERMAS: WITH ASSOCIATED FEATURES

Cole disease (MIM# 615522, ENPP1) is a very rare genodermatosis characterised by congenital or early-onset punctate keratoderma (108). The condition can be AD and AR and is due to ENPP1 mutations which impair homodimerization of the ENPP1 protein leading to impaired melanocyte regulation and function (109).

Over time children develop well-defined hypopigmented macules which are most prominent on the extremities. Cases of associated calcification or tendon calcification have been reported.

PLACK syndrome (MIM# 616295, CAST) is an AR disorder characterised by peeling skin, acral keratoses, leukonychia, cheilitis and knuckle pads caused by mutations in CAST which causes dysregulation of keratinocyte adhesion and apoptosis (110).

CONCLUSION

The PPK are a heterogeneous group of conditions with a biologically fascinating diversity of genetic mutations. Modern sequencing techniques have aided our ability to re-classify these conditions. Targeted gene sequencing and keratoderm specific gene panels will aid in confirming diagnoses.

ACKNOWLEDGEMENTS

ACKNOWLEDGEMENTS

EAO is on the MSAB of Pachyonychia Project.

REFERENCES

1. Schiller S, Seebode C, Hennies HC, Giehl K, Emmert S. Palmoplantar keratoderma (PPK): acquired and genetic causes of a not so rare disease. J Dtsch Dermatol Ges 2014; 12: 781–788.
2. Duchatelet S, Hovnanian A. Olmsted syndrome: clinical, molecular and therapeutic aspects. Orphanet J Rare Dis 2015; 10: 33.
3. Guerra L, Castori M, Didona B, Castiglia D, Zambruno G. Hereditary palmoplantar keratoses. Part I. Non-syndromic palmoplantar keratoses. J Eur Acad Dermatol Venereol 2018; 32: 704–719.
4. Navsaria HA, Swensson O, Ratnave LC, Shamsheer M, McLean WH, Lane EB, et al. Ultrastructural changes resulting from keratin-9 gene mutations in two families with epidermolytic palmoplantar keratoderma. J Invest Dermatol 1995; 104: 425–429.
5. Reis A, Hennies HC, Langbein L, Digweed M, Mischoke D, Drechsler M, et al. Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK). Nat Genet 1994; 6: 174–179.
6. Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003; 4: 347–364.
7. Kuster W, Reis A, Hennies HC. Epidermolytic palmoplantar keratoderma of Veron: re-evaluation of Veron's original family and identification of a novel keratin 9 mutation. Arch Dermatol Res 2002; 294: 268–272.
8. Morley S, Lane E. The keratinocyte cytoskeleton. The keratinocyte handbook. Cambridge University Press is the publisher, Cambridge UK. 1994: p. 293–321.
9. Oji V MD, Traupe H Inherited Disorders of Cornification. Rook’s Textbook of Dermatology. 9th ed: Wiley-Blackwell, Oxford, UK, 2016.
10. Braun-Falco M. Hereditary palmoplantar keratodermas. J Dtsch Dermatol Ges 2009; 7: 971–984; quiz 984–975.
11. Heffner R, van de Kerkhof PC, Traupe H. Retinoids in disorders of keratinization: their use in adults. Dermatologica 1987; 175 Suppl 1: 107–124.
12. Lucker GP, van de Kerkhof PC, Steijlen PM. Topical calcipotriol in the treatment of epidermolytic palmoplantar keratoderma of Verneer. J Dtsch Dermatol 1994; 130: 543–545.
13. Leslie Pedrioli DM, Du DJ, Gonzalez-Gonzalez E, Contag CH, Kaspar RL, Smith FJ, et al. Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder. J Invest Dermatol 2012; 132: 1627–1635.
14. Blaydon DC, Lind KL, Plagnol V, Linton KJ, Smith FJ, Wilson NJ, et al. Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma. Am J Hum Genet 2013; 93: 330–335.
15. Lind L, Lundstrom A, Hofer PA, Holmgren G. The gene for diffuse palmoplantar keratoderma of the type found in northern Sweden is localized to chromosome 12q11-q13. Hum Mol Genet 1994; 3: 1789–1793.
16. Kabashima K, Sakabe J, Yamada Y, Tokura Y. "Nagashima-yo" keratoderma as a novel entity in the palmoplantar keratoderma category. Arch Dermatol 2008; 144: 375–379.
17. Yin J, Xu G, Wang H, Zhao J, Duo L, Cao X, et al. New and recurrent SERPINB7 mutations in seven Chinese patients with Nagashima-type palmoplantar keratoderma. J Invest Dermatol 2014; 134: 2269–2277.
18. Kubo A, Shiohama A, Sasaki T, Nakabayashi K, Kawanishi H, Atsugi T, et al. Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratoderma. Am J Hum Genet 2013; 93: 945–956.
19. Mizuno O, Nomura T, Suzuki S, Takeda M, Oshuchi Y, Fujita Y, et al. Highly prevalent SERPINB7 founder mutation causes pseudodominant inheritance pattern in Nagashima-type palmoplantar keratoderma. Br J Dermatol 2014; 171: 847–853.
20. Bakija-Konsuo A, Basta-Juzbasic A, Rudan J, Situm M, Nardelli-Kovacic M, Levanat S, et al. Mal de Meleda: genetic haplotype analysis and clinicopathological findings in cases originating from the island of Mljet (Meleda), Croatia. Dermatology 2002; 205: 32–39.
21. Fischer J, Bouadjar B, Heilig R, Huber M, Lefevre C, Jobard F, et al. Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum Mol Genet 2001; 10: 875–880.
22. Akbar A, Prince C, Payne C, Fasham J, Ahmad W, Babli EP, et al. Novel nonsense variants in SLURP1 and DSG1 cause palmoplantar keratoderma in Pakistani families. BMC Med Gen 2019; 20: 145.
23. Lestringant GG, Hadi SM, Qayed KI, Blayney BJ. Mal de Meleda: recessive transgressive palmoplantar keratoderma with three unusual facultative features. Dermatology 1992; 184: 78–82.
24. Degos R, Delort J, Charles J. Ahnun aveckératodermie palmo-plantaire. Bull Soc Fr Dermatol Syphiligr 1963; 70: 136–138.
25. Zhao L, Vahlquist A, Virtanen M, Wennerstrand L, Lind KL, Lundstrom A, et al. Palmoplantar keratoderma of the Gamborg-Nielsen type is caused by mutations in the SLURP1 gene and represents a variant of Mal de Meleda. Acta Derm Venereol 2014; 94: 707–710.
26. Mokni M, Charfeddine C, Ben Mously R, Baccouche D, Kaabi B, Ben Osman A, et al. Heterozygous manifestations in female carriers of Mal de Meleda. Clin Genet 2004; 65: 244–246.
27. Park HK, Kim EJ, Ko JY. Alitretinoin: treatment for refractory palmoplantar keratoderma. Br J Dermatol 2016; 174: 1143–1144.
28. van de Kerkhof PC, van Dooren-Greebe RJ, Steijlen PM. Acitretin in the treatment of mal de Meleda. Br J Dermatol 1992; 127: 191–192.
29. Maestri E, Monaco AP, McGrath JA, Ishida-Yamamoto A, Camisa C, Hovnanian A, et al. A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel’s syndrome. Nat Genet 1996; 13: 70–77.
30. Matsumoto K, Muto M, Seki S, Saida T, Horie N, Takahashi H, et al. Loricrin keratoderma: a cause of congenital ichthyosiform erythroderma and collodion baby. Br J Dermatol...
Theme issue: Genodermatoses

Inherited palmoplantar keratodermas

175

Acta Dermato-Venereologica

2001; 145: 657–660.

31. Gedeker MM, Traupe H, Fischer B, Tinschert S, Hennies HC. Towards characterization of palmoplantar keratodermia caused by different factor mutations in loricrin: analysis of a family and review of the literature. Br J Dermatol 2006; 154: 167–171.

32. Pohler E, Cunningham F, Sandilands A, Cole C, Digby S, McMillan JR, et al. Novel autosomal dominant mutation in loricrin protein as prominent ichthyosis. Br J Dermatol 2005; 153: 1291–1294.

33. Camisa C, Rossana C. Variant of keratoderma hereditaria mutans (Vohwinkel's syndrome). Treatment with orally adminis- tered isoretinoin. Arch Dermatol 1984; 120: 1323–1328.

34. Yoneda K, Demitsu T, Nakai K, Monieu T, Ogawa W, Igarashi J, et al. Activation of vascular endothelial growth factor receptor 2 in a cellular mouse of loricin keratoderma. J Biol Chem 2010; 285: 16184–16194.

35. Vahlquist A, Ponten F, Pettersson A. Keratosis linearis with ichthyosis congenita and sclerosing keratoderma (KLICK-syndrome): a rare, autosomal recessive disorder of kerato- hyaline formation? Acta Derm Venereol 1997; 77: 225–227.

36. Dahlqvist J, Klar J, Tiwari N, Schuster J, Torma H, Badhai J, et al. A single-nucleotide deletion in the POMP 5' UTR causes a transcriptional switch and altered epidermal proteasome distribution in KLICK gendermalerosis. Am J Hum Genet 2010; 86: 596–603.

37. Dahlqvist J, Klar J, Badhai J, Dahl N. siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK gendermalerosis. PLoS One 2012; 7: e29471.

38. van Steensel MA, van Geel M, Steijlen PM. A new type of erythrodermatoderma. Br J Dermatol 2005; 152: 155–158.

39. Gunther C, Lee-Kirsch MA, Eckardt J, Matanovic A, Kerscher M, et al. WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated cell cycling. J Invest Dermatol 2005; 125: 136: 1722–1729.

40. Eytan O, Fuchs-Telem D, Mavorbach B, Indelman M, Bergman R, Sarig O, et al. Olmsted syndrome caused by a homozy- gous recessive mutation in TRPV3. J Invest Dermatol 2014; 134: 1752–1754.

41. Lin Z, Chen Q, Lee M, Cao X, Zhang J, Ma D, et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am J Hum Genet 2012; 90: 558–564.

42. Oeffner F, Fischer G, Happle R, König A, Betz RC, Bornholdt D, et al. IFAP syndrome is caused by deficiency in MBTPS2, an intramembrane zinc metalloprotease essential for chole- terol homeostasis and ER stress response. Am J Hum Genet 2009; 84: 459–467.

43. Wilson NJ, Cole C, Mistleton LM, Kisewzki AE, Hansen CD, O’Toole EA, et al. Expanding the phenotypic spectrum of Olmsted syndrome. J Invest Dermatol 2015; 135: 2879–2883.

44. Tao J, Huang CZ, Yu NW, Wu Y, Liu YQ, Li Y, et al. Olmsted syndrome: a systematic review and meta-analysis. J Med Genet 2008; 47: 432–437.

45. Kenner-Bell BM, Paller AS, Lacouture ME. Epidermal growth factor receptor inhibitor with erlotinib for palmoplantar kerato- derma. J Am Acad Dermatol 2010; 63: e58–59.

46. Hart TC, Hart PS, Micheal MC, Zhang Y, Marazita ML, Cooper M, et al. Localisation of a gene for prepubertal periodontitis to chromosome 11q14 and identification of a cathepsin C gene mutation. J Med Genet 2000; 37: 95–101.

47. Toomes C, James J, Wood AJ, Wu CL, McCormick D, Lench N, et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet 2000; 23: 421–424.

48. Ulbrico C, Cossner CG, Nederfors T, Alfadley A, Thestrup-Pedersen K. Dermatologic and oral findings in a cohort of 47 patients with Papillon-Lefevre syndrome. Am J Acad Dermatol 2003; 48: 345–351.

49. Posteraro AF. Papillon-Lefevre syndrome. Journal - Alabama Dental Association 1992; 76: 16–19.

50. Bergman R, Friedman-Birnbaum R. Papillon-Lefevre syn- drome: a study of the long-term clinical course of recurrent pyogenic infections and the effects of etretinate treatment. Br J Dermatol 1988; 119: 731–736.

51. Hart TC, Hart PS, Michael MC, Zhang Y, Firatli E, Van Dyke TE, et al. Haim-Munk syndrome and Papillon-Lefevre syn- drome are allelic mutations in cathepsin C. J Med Genet 2000; 37: 88–94.

52. French D, Scott H, Overall CM. Papillon-Lefevre syndrome associated early onset periodontitis: a review and case study. J Can Dent Assoc 1992; 58: 432–438.

53. Sprecher E, Ishida-Yamamoto A, Mizrahi-Koren M, Rapaport D, Goldshier D, Indelman M, et al. A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma. Am J Hum Genet 2005; 77: 242–251.

54. Fuchs-Telem D, Steward H, Rapaport D, Nourse J, Gati A, Gini M, et al. CEDNIK syndrome results from loss-of-function mutations in SNAP29. Br J Dermatol 2011; 164: 610–616.

55. Gruber R, Rogerson C, Windpassinger C, Banushi B, Stra- atman-Iwanowska A, Hanley J, et al. Autosomal recessive keratoderma-ichthyosis-deafness (ARKID) syndrome is caused by VPS33B mutaitons affecting rab protein interaction and collagen modification. J Invest Dermatol 2017; 137: 845–854.

56. Maruthappu T, Papillon-Lefevre syndrome. J Can Dent Assoc 1995; 61: 432–438.

57. Hart TC, Hart PS, Michael MC, Zhang Y, Firatli E, Van Dyke TE, et al. Haim-Munk syndrome and Papillon-Lefevre syn- drome are allelic mutations in cathepsin C. J Med Genet 2000; 37: 88–94.

58. French D, Scott H, Overall CM. Papillon-Lefevre syndrome associated early onset periodontitis: a review and case study. J Can Dent Assoc 1992; 58: 432–438.

59. Sprecher E, Ishida-Yamamoto A, Mizrahi-Koren M, Rapaport D, Goldshier D, Indelman M, et al. A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma. Am J Hum Genet 2005; 77: 242–251.

60. Gruber R, Rogerson C, Windpassinger C, Banushi B, Stra- atman-Iwanowska A, Hanley J, et al. Autosomal recessive keratoderma-ichthyosis-deafness (ARKID) syndrome is caused by VPS33B mutaitons affecting rab protein interaction and collagen modification. J Invest Dermatol 2017; 137: 845–854.

61. Maruthappu T, Papillon-Lefevre syndrome. J Can Dent Assoc 1995; 61: 432–438.
81. McLean WH, Hansen CD, Eliason MJ, Smith FJ. The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol 2010; 130: 425–429.
82. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol 2012; 67: 680–686.
83. Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol 2014; 150: 146–153.
84. Wilson NJ, Messenger AG, Leachman SA, O’Toole EA, Lane EB, McLean WH, et al. Keratin K6c mutations cause focal palmparantar keratoderma. J Invest Dermatol 2010; 130: 425–429.
85. Swartling C, Karlqvist M, Hymnelius K, Weiss J, Vahliquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol 2010; 163: 1072–1076.
86. Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Invest Dermatol Sci 2009; 56: 82–88.
87. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010; 18: 442–446.
88. Van Steensel MA, Van Geel M, Steijlen PM. New syndrome of hypotrichosis, striate palmparantar keratoderma, acroosteolysis and periodontitis not due to mutations in cathepsin C. Br J Dermatol 2002; 147: 575–581.
89. Bun AM, Van Steensel MAM. A third case of HOPP syndrome – onfirmaion of the phenotype. Br J Dermatol 2004; 150: 1032–1033.
90. Kellson DP, Di WL, Houseman MJ. Connexin mutations in skin disease and hearing loss. Am J Hum Genet 2001; 68: 559–568.
91. van Steensel MA. Gap junction diseases of the skin. Am J Med Genet C Semin Med Genet 2004; 131c: 12–19.
92. Sensi A, Bettioli V, Zamponi MR, Gandini E, Calzolari E. Vohwinkel syndrome (mutilating keratoderma) associated with craniofacial anomalies. Am J Med Genet 1994; 50: 201–203.
93. Bondeson ML, Nyström AM, Gunnarsson U, Vahliquist A. Connexin 26 (GJB2) mutations in two Swedish patients with atypical Vohwinkel (mutilating keratoderma plus deafness) and KID syndrome both extensively treated with actretin. Acta Derm Venerolog 2006; 86: 503–508.
94. Protonotarios N, Tsatsopoulou A. Naxos disease: cardiovacularaneous syndrome due to cell adhesion defect. Orphanet J Rare Dis 2006; 1: 4.
95. Norgett EE, Hatseij SJ, Carvalhal-Huerta L, Cabezud JC, Com J, Purks PE, et al. Rescessive mutation in desmoplakin disrupts desmoplakin-remmiate filament interactions and causes dilated cardiovacularaneous, woolly hair and keratoderma. Hum Mol Genet 2000; 9: 2761–2766.
96. Norgett EE, Lucke TW, Bowers B, Munro NS, Leigh IM, Kellsell DP. Early death from cardiovacularaneous in a family with autosomal dominant striate palmparantar keratoderma and woolly hair associated with a novel insertion mutation in cytokeratin 17. Mucocutaneous and Molecular Genetics 2005; 126: 106–110.
97. Uzumcu A, Norgett EE, Dindar A, Uygurer N, Nisli K, Kayseri D, et al. Loss of desmoplakin isoform I causes early onset cardiovacularaneous and heart failure in a Naxos-like syndrome. J Med Genet 2006; 43: e5.
98. Ramot Y, Milho-Pessam V, Meier T, Alper-Pinus R, Siam I, Tams S, et al. Mutation in KANK2, encoding a sequestering protein for steroid receptor coactivators, causes keratoderma and woolly hair. J Med Genet 2014; 51: 388–394.
99. Pohler E, Mami O, Hirish J, Zarni M, Horn H, Nomura T, et al. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmparantar keratoderma. Nature Genet 2012; 44: 1272–1276.
100. Furniss M, Higgins CA, Martinez-Mir A, Horev L, Petukhova L, Stanimirovic A, et al. Identification of distinct mutations in AAGAB in families with type 1 punctate palmparantar keratoderma. J Invest Dermatol 2014; 134: 1749–1752.
101. Guo BR, Zhang X, Chen G, Zhang JG, Sun LD, Du WD, et al. Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmparantar keratoderma. J Med Genet 2012; 49: 563–568.
102. Emmert S, Kuster W, Hennies HC, Zutt M, Haenssle H, Kretschmer L, et al. 47 patients in 14 families with the rare genodermatosis keratosis punctata palmparantarbusche-Kasper-Brauer. Eur J Dermatol 2003; 13: 16–20.
103. Hesse S, Berbis P, Privat Y. Keratoderma palmparantar-papulosus (Busche-Kasper’s disease): efficacy of actretin. Br J Dermatol 1993; 128: 104–105.
104. Moulin C, Petitot-Roland A, Chouvet B, Faure M, Claudy A. Acrokeratolalasealodésléase unilatérale. Ann Dermatol Venereol 1996; 123: 654–656.
105. Dowd PM, Harman RR, Black MM. Focal acral keratoderma. Br J Dermatol 1983; 109: 97–103.
106. Cabrol C, Bienvenu T, Ruaud L, Girodon E, Noacco G, Delobeau D. Kératodermie palmoplantaire aquagénique chez un patient. Ann Dermatol Venereol 1996; 123: 575–581.
107. Well B, Chaillou E, Troussier F, Pelatan C, Chiffelleau M, Dar Viot E, et al. Kératodermie palmoplantaire acquagénique chez l’enfant mucoviscidosique. Arch Pediatr 2013; 20: 1306–1309.
108. Cole LA. Hypopigmentation with punctate keratoderma of the palms and soles. Arch Dermatol 1976; 112: 998–1000.
109. Chourabi M, Liew MS, Lim S, H’Mida-Ben Brahim D, Boussofa L, Dai L, et al. ENPP1 Mutation Causes Recessive Clole Disease by Altering Melanogenesis. J Invest Dermatol 2018; 138: 291–300.
110. Lin Z, Zhao J, Nitoiu D, Scott CA, Plagno V, Smith FJ, et al. Loss-of-function mutations in CASP cause peeling skin, leukonychia, acral punctate keratodes, chelitis, and knuckle pads. Am J Hum Genet 2015; 96: 440–447.